Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10773784 | 0.93 | NPSR1 (0.40) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL10473858 | 0.90 | MEN1 (0.40) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL7010290 | 0.89 | MAPT (0.41) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL7054038 | 0.88 | MEN1 (0.42) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL10774566 | 0.86 | GPR35 (0.39) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5525144 | 0.86 | NPSR1 (0.39) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL10630627 | 0.86 | MEN1 (0.39) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL7005347 | 0.86 | NPSR1 (0.39) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL5525140 | 0.86 | NPSR1 (0.39) | NPSR1MEN1KMT2AMAPTLMNA | |
| SCHEMBL29733801 | 0.86 | NPSR1 (0.39) | NPSR1MEN1KMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-09-13 | — | — | US | disclosed |
| EP-1732897-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | Bayer Pharmaceuticals Corporation (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2005097752-A1 | QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-0945435-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0952151-B1 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0992501-B1 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMA CO LTD (JP) | 2002-08-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6136823-A | BACTERICIDES OR VIRICIDES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0366149-B1 | IMPROVED PROCESS FOR THE SYNTHESIS OF 3-CHLORO-2,4,5-TRIFLUOROBENZOIC ACID | WARNER-LAMBERT COMPANY (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5072038-A | Chemical intermediates for bactericides | BAYER AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |
| EP-0366149-A1 | Improved process for the synthesis of 3-chloro-2,4,5-trifluorobenzoic acid | WARNER-LAMBERT COMPANY (US) | 1990-05-02 | — | — | EP | disclosed |
| US-4885386-A | Process for the synthesis of 3-chloro-2,4,5-trifluorobenzoic acid | WARNER-LAMBERT COMPANY (US) | 1989-12-05 | — | — | US | disclosed |
| EP-0183129-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1989-08-09 | — | — | EP | disclosed |
| US-4771054-A | QUINOLINE CARBOXYLIC ACID | WARNER-LAMBERT COMPANY (US) | 1988-09-13 | — | — | US | disclosed |
| EP-0235762-A1 | 8-Position substituted quinolone-carboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
| EP-0195841-A1 | Quinolinecarboxylic acid derivatives and process for their preparation | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-10-01 | — | — | EP | disclosed |
| EP-0195316-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-09-24 | — | — | EP | disclosed |
| EP-0183129-A1 | Quinolonecarboxylic acid derivatives | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 1986-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213339-A1 | Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions | TP53, RB1, HRAS | NPSR1 4427/4885MEN1 1653/4885KMT2A 2389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.